Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II induction TPF followed by hyperfractionated concomitant boost radiotherapy with cetuximab in locally advanced laryngeal or hypopharyngeal carcinoma
2008-003365-29Phase 2Active
- Sponsor
- Grupo de Investigación Clínica en Oncología Médica
- Start
- Sep 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, cisplatin and fluorouracil in laryngeal squamous cell carcinoma (LSCC) and squamous cell carcinoma of the hypopharynx, sponsored by Grupo de Investigación Clínica en Oncología Médica. Primary endpoint: Progression-free survival at 2 years. Started Sep 2008; status: active.
02
Drugs
cetuximabcisplatinfluorouracil
03
Conditions
laryngeal squamous cell carcinoma (LSCC)squamous cell carcinoma of the hypopharynx
Beyond the preview
Go deeper on 2008-003365-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003365-29.